Keybank National Association Nektar Therapeutics Transaction History

Keybank National Association

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 30, 2019	SELL	$30.43 - $56.65 $627,953 - $1.17 Million	-20,636 Closed	0 $0
Q3 2018 Nov 08, 2018	SELL	$46.46 - $68.49 $45,995 - $67,805	-990 Reduced 4.58%	20,636 $1.26 Million
Q2 2018 Aug 08, 2018	BUY	$46.25 - $104.45 $217,930 - $492,168	4,712 Added 27.86%	21,626 $1.06 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $970,863 - $1.83 Million	16,914 New	16,914 $1.8 Million

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $247M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

Stay updated on Keybank National Association with notifications on news.